Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Fever management practices among sickle cell disease programs in low and middle-income countries
source: American Society of Pediatric Hematology/Oncology
year: 2016
authors: Catherine Taylor, Alexandra Coria, Venée N. Tubman
summary/abstract:Under-5 mortality for children with sickle cell disease (SCD) in low and middle-income countries (LMIC) is high, with the majority of deaths likely related to infectious complications. In the United States, dramatic decreases in childhood mortality for SCD over the past 40 years have been aided by interventions to reduce mortality associated with infections. In LMIC, these interventions (i.e. penicillin prophylaxis, rapid investigation and treatment of febrile illness, and vaccination) may not be consistently available.
Design/Method: A survey of English and French-speaking providers at SCD programs in LMIC. The survey was available online and offline, distributed via email distribution lists, at applicable meetings, and by referral.
Results: Providers from 13 LMIC returned 27 interpretable surveys, including 23 from malaria-endemic areas. Newborn screening is associated with 34% (n=10/27) of programs. Pneumococcal conjugate vaccine is available at 66% (n=14/25) of programs. Penicillin prophylaxis is prescribed to some or all patients by 65% (n=17/26) of respondents. Malaria prophylaxis is prescribed by 83% (n=19/23) in malarial-endemic areas. Forty-eight percent of programs (n=14/27) have written fever management protocols. To patients with SCD presenting with fever, 21% (n=5/24) of respondents ‘always’ give antibiotics, although 54% (n=13/24) give antibiotics ‘almost always’. First line antibiotics are given orally by 27% (n=7/26); 77% (n=20/26) would consider oral antibiotics in some circumstances. The preferred first line antibiotic is ceftriaxone for 9/19 giving IV/IM antibiotics and amoxicillin-clavulanate for 4/7 giving oral antibiotics. At programs in malaria-endemic areas, 79% (n=18/23) ‘always’ or ‘almost always’ give antimalarials to febrile patients. Forty-six percent (n=12/26) of respondents report that a majority of febrile patients receive antibiotics prior to presentation. In malaria-endemic areas, 74% (n=17/23) report that a majority receive antimalarials prior to presentation.
read more
+myBinderRelated Content
-
Sickle cell disease is associated with higher mortality among patients hospitalized with ischemic bowel diseaseBackground: Sickle cell disease (SCD) i...
-
FDA grants CRISPR gene therapy fast track designation for sickle cell diseaseThe FDA granted fast track designation t...
-
Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in...Sickle cell disease can be complicated b...
-
NIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global ScaleThe National Institutes of Health plans ...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.